{"id":756519,"date":"2023-05-09T09:46:07","date_gmt":"2023-05-09T13:46:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/"},"modified":"2023-05-09T09:46:07","modified_gmt":"2023-05-09T13:46:07","slug":"immutep-to-participate-in-the-jmp-securities-life-sciences-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/","title":{"rendered":"Immutep to Participate in the JMP Securities Life Sciences Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        <strong>Media Release<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>SYDNEY, AUSTRALIA, May  09, 2023  (GLOBE NEWSWIRE) &#8212; <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rR3LYZrY5mAKH5BeS46tsCxogQNuT4iXmLomWbrmqWI-ujDpckLACAurI8tcyz_gfM73NtIBpQSS5a1sO-5Zbg==\" rel=\"nofollow noopener\" target=\"_blank\">Immutep Limited<\/a> (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present and be available for 1-on-1 meetings at the\u00a0JMP\u00a0Securities Life Sciences Conference, on Tuesday, May 16<sup>th<\/sup>, 2023. Presentation details:<\/p>\n<p align=\"justify\">The JMP Securities Life Sciences Conference <br \/>Location: New York Hilton Midtown, 1335 Avenue of the Americas<br \/>Date: Tuesday, May 16th<br \/>Presentation time: 3:00PM ET<\/p>\n<p align=\"justify\">\n        <strong>About Immutep<\/strong><br \/>\n        <br \/>Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=df7dC6YeDJad_P_rvY6sasFT6x4Pfqd7pGxDg3r3CP6xmdHQfYptr1mnEctKt-2RBwT3RR5cYLI-hV-B2MJRWA==\" rel=\"nofollow noopener\" target=\"_blank\">www.immutep.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Australian Investors\/Media:<\/strong><br \/>\n        <br \/>Catherine Strong, Citadel-MAGNUS<br \/>+61 (0)406 759 268; <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KbWsICfOts0UGZ-NCzgQinrw0jsyX1t0igE_i3BILXQgeClxm5cNWqx8koNbR7_ZeLsWcAphTBnmXk5z79TTJG2HYdT_iuWDzU9T9Gk58Qg=\" rel=\"nofollow noopener\" target=\"_blank\">cstrong@citadelmagnus.com<\/a><\/u><\/p>\n<p align=\"justify\">\n        <strong>U.S. <\/strong><br \/>\n        <strong>Investors\/<\/strong><br \/>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Chris Basta, VP, Investor Relations and Corporate Communications<br \/>+1 (631) 318 4000; <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rTymoxscDCgT4JhT14-n8azzyGiE74UgVz9B0Gdg4vql2x-eUBdJ92O_fGwyyFD4Mf5_aLrwyHkgc_4FtfEbR-iT_6474wsXc8SNUpAztEg=\" rel=\"nofollow noopener\" target=\"_blank\">chris.basta@immutep.com<\/a><\/u><\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDc3OCM1NTgyOTYzIzIwMTk4MzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2QxNWUyODQtZDA4MS00NTdjLTgwMzktMmVkYWE3MWVhZjU3LTEwMzE0MDU=\/tiny\/Immutep-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present and be available for 1-on-1 meetings at the\u00a0JMP\u00a0Securities Life Sciences Conference, on Tuesday, May 16th, 2023. Presentation details: The JMP Securities Life Sciences Conference Location: New York Hilton Midtown, 1335 Avenue of the AmericasDate: Tuesday, May 16thPresentation time: 3:00PM ET About Immutep Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immutep to Participate in the JMP Securities Life Sciences Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-756519","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immutep to Participate in the JMP Securities Life Sciences Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immutep to Participate in the JMP Securities Life Sciences Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present and be available for 1-on-1 meetings at the\u00a0JMP\u00a0Securities Life Sciences Conference, on Tuesday, May 16th, 2023. Presentation details: The JMP Securities Life Sciences Conference Location: New York Hilton Midtown, 1335 Avenue of the AmericasDate: Tuesday, May 16thPresentation time: 3:00PM ET About Immutep Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its &hellip; Continue reading &quot;Immutep to Participate in the JMP Securities Life Sciences Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-09T13:46:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDc3OCM1NTgyOTYzIzIwMTk4MzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immutep to Participate in the JMP Securities Life Sciences Conference\",\"datePublished\":\"2023-05-09T13:46:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\\\/\"},\"wordCount\":192,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDc3OCM1NTgyOTYzIzIwMTk4MzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\\\/\",\"name\":\"Immutep to Participate in the JMP Securities Life Sciences Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDc3OCM1NTgyOTYzIzIwMTk4MzM=\",\"datePublished\":\"2023-05-09T13:46:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDc3OCM1NTgyOTYzIzIwMTk4MzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDc3OCM1NTgyOTYzIzIwMTk4MzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immutep to Participate in the JMP Securities Life Sciences Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immutep to Participate in the JMP Securities Life Sciences Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/","og_locale":"en_US","og_type":"article","og_title":"Immutep to Participate in the JMP Securities Life Sciences Conference - Market Newsdesk","og_description":"Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present and be available for 1-on-1 meetings at the\u00a0JMP\u00a0Securities Life Sciences Conference, on Tuesday, May 16th, 2023. Presentation details: The JMP Securities Life Sciences Conference Location: New York Hilton Midtown, 1335 Avenue of the AmericasDate: Tuesday, May 16thPresentation time: 3:00PM ET About Immutep Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its &hellip; Continue reading \"Immutep to Participate in the JMP Securities Life Sciences Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-09T13:46:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDc3OCM1NTgyOTYzIzIwMTk4MzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immutep to Participate in the JMP Securities Life Sciences Conference","datePublished":"2023-05-09T13:46:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/"},"wordCount":192,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDc3OCM1NTgyOTYzIzIwMTk4MzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/","name":"Immutep to Participate in the JMP Securities Life Sciences Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDc3OCM1NTgyOTYzIzIwMTk4MzM=","datePublished":"2023-05-09T13:46:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDc3OCM1NTgyOTYzIzIwMTk4MzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDc3OCM1NTgyOTYzIzIwMTk4MzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-to-participate-in-the-jmp-securities-life-sciences-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immutep to Participate in the JMP Securities Life Sciences Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/756519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=756519"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/756519\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=756519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=756519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=756519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}